房颤抗凝患者超声心动图卒中风险因素与结局
基于ARISTOTLE试验的事后分析纳入1251例房颤患者,比较自发性回声增强、左房/左心耳血栓和复杂主动脉斑块与无上述发现者的临床结局,并评估阿哌沙班与华法林的疗效安全性。结果显示这些超声心动图发现并未显著增加卒中/体循环栓塞风险,阿哌沙班与华法林疗效无显著差异。
要点
- 房颤抗凝患者中,自发性回声增强、左房/左心耳血栓或复杂主动脉斑块未显著增加卒中/体循环栓塞风险。
- 上述超声发现与缺血性卒中、心肌梗死、心血管死亡及全因死亡风险无显著差异。
- 阿哌沙班与华法林疗效无显著差异,仅无左房/左心耳血栓者阿哌沙班在死亡和出血方面获益更明显。
核心结论
- 在接受抗凝治疗的房颤合并卒中风险因素患者中,超声心动图发现的自发性回声增强、左房/左心耳血栓或复杂主动脉斑块未显著增加血栓栓塞事件风险。
研究设计与样本
- ARISTOTLE试验事后分析,纳入1251例房颤患者,其中自发性回声增强217例、左房/左心耳血栓127例、复杂主动脉斑块241例、无上述发现746例。
主要发现
- 卒中/体循环栓塞发生率在有无上述超声发现者间无显著差异:自发性回声增强HR 0.96(95%CI 0.25-3.60),左房/左心耳血栓HR 1.27(95%CI 0.23-6.86),复杂主动脉斑块HR 2.21(95%CI 0.71-6.85)。
- 缺血性卒中、心肌梗死、心血管死亡及全因死亡发生率在有无上述发现者间亦无差异。
- 对于自发性回声增强或复杂主动脉斑块患者,阿哌沙班与华法林疗效无差异证据;对于左房/左心耳血栓患者,除全因死亡和任何出血外无显著交互作用,无左房/左心耳血栓者阿哌沙班较华法林获益更大。
临床怎么用
- 对于已接受抗凝治疗的房颤患者,超声心动图发现的自发性回声增强、左房/左心耳血栓或复杂主动脉斑块不宜单独作为强化抗栓治疗的依据。
- 阿哌沙班与华法林在上述超声发现患者中的疗效和安全性总体相似,临床选择抗凝药物时可综合考虑其他因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Few data exist on the long-term outcomes of patients with spontaneous echo contrast (SEC), left atrial/left atrial appendage (LA/LAA) thrombus, and complex aortic plaque (CAP), in patients with atrial fibrillation receiving oral anticoagulation. We explored the relationship between these 3 echocardiographic findings and clinical outcomes, and the comparative efficacy and safety of apixaban and warfarin for each finding. METHODS: Patients from the ARISTOTLE trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) with SEC, LA/LAA thrombus, or CAP diagnosed by either transthoracic or transesophageal echocardiography were compared with patients with none of these findings on transesophageal echocardiography. RESULTS: A total of 1251 patients were included: 217 had SEC, 127 had LA/LAA thrombus, 241 had CAP, and 746 had none. The rates of stroke/systemic embolism were not significantly different among patients with and without these echocardiographic findings (hazard ratio, 0.96; 95% confidence interval, 0.25-3.60 for SEC; hazard ratio, 1.27; 95% confidence interval, 0.23-6.86 for LA/LAA thrombus; hazard ratio, 2.21; 95% confidence interval, 0.71-6.85 for CAP). Rates of ischemic stroke, myocardial infarction, cardiovascular death, and all-cause death were also not different between patients with and without these findings. For patients with either SEC or CAP, there was no evidence of a differential effect of apixaban over warfarin. For patients with LA/LAA thrombus, there was also no significant interaction, with the exception of all-cause death and any bleeding where there was a greater benefit of apixaban compared with warfarin among patients with no LA/LAA thrombus. CONCLUSIONS: In anticoagulated patients with atrial fibrillation and risk factors for stroke, echocardiographic findings do not seem to add to the risk of thromboembolic events. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00412984.
引用
- Vinereanu D, Lopes RD, Mulder H, et al. Echocardiographic Risk Factors for Stroke and Outcomes in Patients With Atrial Fibrillation Anticoagulated With Apixaban or Warfarin. Stroke. 2017. PMID: 29089455. doi:10.1161/STROKEAHA.117.017574
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。